Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

ss release remain subject to audit and confirmation procedures, and therefore the results may change materially and adversely after such procedures are completed; (vi) the data in this press release is not necessarily predictive of the outcome of the expansion arm of the Phase 2 study of NKTR-102 in patients with platinum resistant/refractory ovarian that have received prior treatment with PLD—therefore the results from this expanded Phase 2 study population could be materially and adversely different than the results described in this press release; (vii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in ovarian cancer (including without limitation the expansion arm of the study) and therefore the future results from this ongoing Phase 2 ovarian cancer study may differ materially and adversely from the preliminary interim results presented in this press release; (viii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (ix) the uncertain outcome of any future intellectual property, commercial or other litigation related to Nektar's proprietary product candidates, including without limitation NKTR-102; and (x) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed with the Securities and Exchange Commission on April 29, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, including but not limited to any clinical, FDA or other regulatory information, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nekta
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- According to data released today by the Centers for ... Part D premium is expected to remain stable at ... the Pharmaceutical Care Management Association (PCMA) said. ... bright spot in American health care. By offering an ... cutting edge, cost-saving tools like pharmacy networks and home ...
(Date:7/29/2015)... Company (NASDAQ: STAA ), a leading developer, manufacturer and ... today reported financial results for the second quarter ended July ... Net Sales of $18.7 Million Down 7% from the Prior ... from the Weakening Euro and Yen , ICL Units ... APAC Sales Down 1% Including Korea - Up 16% Excluding ...
(Date:7/29/2015)... SAN DIEGO, July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: ... ended June 30, 2015. For the second quarter of 2015, the ... per share, compared to a net loss of $13.4 million, or ... the six months ended June 30, 2015, the Company reported a ... compared to net loss of $25.2 million, or $0.35 loss per ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9
... Pa., Jan. 10, 2011 In its ... care management , B. Braun Medical Inc. (B. Braun) ... PHMB (Polyhexanide) , a product used in the healthcare ... lubricating absorbent wound dressings, is now available for over-the-counter ...
... Jan. 10, 2011 Hotspur Technologies, Inc. announced ... Stephen Liu, M.D., Interventional Radiologists at Lifelink Interventional ... deployment of the company,s GPSCath™ Balloon Dilatation Catheter. ... multiple vascular procedures to be performed with one ...
Cached Medicine Technology:B. Braun Offers Wound Patients a New 'Over-the-Counter' Wound Management Gel - Prontosan® 2B. Braun Offers Wound Patients a New 'Over-the-Counter' Wound Management Gel - Prontosan® 3Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market 2Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market 3
(Date:7/30/2015)... ... 30, 2015 , ... Addictions Training Institute has announced the launch ... Alcohol and Substance Abuse Counselors. , "We are thrilled to be launching Addictions Training ... shortage of Alcohol and Drug Counselors nationwide. We are excited to be helping ...
(Date:7/29/2015)... ... ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search for ... art was used for the Charlotte Coliseum show a month later. According to Hawley, ... style concert posters. , They measure 22 x 28 inches and were printed ...
(Date:7/29/2015)... ... July 30, 2015 , ... In ... BOC approved provider of online continuing education courses for Athletic Trainers , ... exclusive Andrews Research and Education Sports Medicine Series. , The new online continuing ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to data released today ... D premium is expected to remain stable at $32.50, a figure far lower than ... D program continues to be a bright spot in American health care. By offering ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to an article published July 23 ... of Health shows exactly what a person needs to do in terms of physical activity ... app will give informed estimates as to the number of calories a person needs to ...
Breaking Medicine News(10 mins):Health News:Addictions Training Institute Announces New Online Certificate Program for Alcohol and Drug Counselors 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:New NIH Body Weight Planner Illustrates the Need for Reduced Caloric Intake When Trying to Lose Weight, Says Beverly Hills Physicians 2
... A new study provides a novel theory for how ... Center researcher Orrin Devinsky, MD, performed an in-depth analysis ... a consistent pattern of injury to the frontal lobe ... deficits caused by these injuries to the right hemisphere, ...
... than three-quarters of young violent offenders interviewed in two poverty-stricken ... violent incident, a new study reveals. , About half of ... said they had a close friend who died in a ... violence may lead some inner-city youth to accept violence as ...
... & Johnson will host an analyst meeting at 8:30 ... discuss fourth-quarter and full-year 2008 financial results. The meeting ... Chief Executive Officer.Investors and other interested parties may access ... Company,s website at www.investor.jnj.com . , A webcast ...
... Born no larger than a ballpoint pen at birth, ... named the 2009 National Ambassador for the March of Dimes, ... Virginia, was born very early at 25 weeks, weighing less ... only a 5 percent chance of survival. During her five-month ...
... health care , , TUESDAY, Jan. 13 (HealthDay News) -- ... approach adulthood to ensure they receive proper health care as ... Peter Scal of the University of Minnesota, found only about ... such as obtaining health insurance after coming of age. This ...
... 13 Availity, LLC was recognized,as the 2008 ... at the eighth,annual Excellence in Employee Development Awards ... University of North Florida (UNF) Division of ... along with other award winners, at a luncheon ...
Cached Medicine News:Health News:Delusions associated with consistent pattern of brain injury 2Health News:Delusions associated with consistent pattern of brain injury 3Health News:Study: Most young violent offenders in two NYC neighborhoods have seen someone killed 2Health News:Study: Most young violent offenders in two NYC neighborhoods have seen someone killed 3Health News:Study: Most young violent offenders in two NYC neighborhoods have seen someone killed 4Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 2Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 3Health News:Availity Achieves Excellence in Blended Learning Award 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
... Difficile Tox A/B II is a second-generation rapid ... A and B in fecal specimens. The test ... results detecting not only the more common toxin ... A-/B+. It's easy to perform, produces no indeterminates ...
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
Medicine Products: